Scott A Busby; Seth Carbonneau; John Concannon; Christoph E. Dumelin; YounKyoung Lee; Shin Numao; Nicole Renaud; Thomas M Smith; Douglas S. Auld
ACS Chem. Biol., 2020, 15(10), 2636-2648
https://doi.org/10.1021/acschembio.0c00495

Abstract

Assays drive drug discovery from the exploratory phases to the clinical testing of drug candidates. As such, numerous assay technologies and methodologies have arisen to support drug discovery efforts. Robust identification and characteri-zation of tractable chemical matter requires biochemical, biophysical, and cellular approaches and often benefits from high-throughput methods. To increase throughput, efforts have been made to provide assays in miniaturized volumes which can be arrayed in microtiter plates to support the testing of as many as 100,000 samples/day. Alongside these ef-forts has been the growth of microtiter plate-free formats with encoded libraries that can support the screening of billions of compounds, a hunt for new drug modalities, as well as emphasis on more disease relevant formats using complex cell models of disease states. This review will focus on recent developments in high-throughput assay technologies applied to identify starting points for drug discovery. We also provide recommendations on strategies for implementing various as-say types to select high quality leads for drug development.